

Appl. No. : 10/785,446  
Filed : February 23, 2004

### REMARKS

Applicants have amended Paragraph [0010] of the specification and Claims 8, 20, and 23 to correct an inadvertent error in the drawing of the compound of Formula I. Applicants had neglected to include the nitrogen atom at position 3 of the xanthine core structure, which error is hereby corrected by the present amendments.

Applicants respectfully submit that the present amendments add no new matter and are fully supported by the specification as originally filed. Paragraph [0010] of the specification of the above-captioned application discloses that the "AA<sub>1</sub>RA used in the pharmaceutical compositions or methods disclosed herein may be a xanthine-derivative compound." Those of skill in the art recognize that a xanthine core compound comprises four nitrogen atoms, to wit: at positions 1, 3, 5 and 7. The compound of Formula I is clearly identified in the specification as a xanthine-derivative compound. Paragraphs [0015] and [0016] also describe xanthine-derivative compounds, in which position 3 of the ring is a nitrogen atom. Therefore, the present amendments only correct what has already been disclosed in the application.

Furthermore, Applicants respectfully submit that the amendments to the claims in no way limit the scope of the claims and only serve to correct the structure of the compound of Formula I.

No fee is believed due in connection with this amendment. If this is incorrect, please charge any required additional fees to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

May 18, 2004

By:

Sam K. Tahmassebi  
Sam K. Tahmassebi  
Registration No. 45,151  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550